PA
CRNX

Profund Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Profund Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Buy
9,508
+1,493
+19% +$55.5K 0.01% 704
2026
Q1 		$291K Buy
8,015
+1,065
+15% +$47.6K 0.01% 764
2025
Q4 		$324K Sell
6,950
-3,141
-31% -$140K 0.01% 815
2025
Q3 		$420K Sell
10,091
-9,606
-49% -$307K 0.01% 584
2025
Q2 		$566K Sell
19,697
-2,220
-10% -$68.6K 0.02% 435
2025
Q1 		$735K Buy
21,917
+5,032
+30% +$188K 0.03% 370
2024
Q4 		$863K Sell
16,885
-3,176
-16% -$178K 0.03% 322
2024
Q3 		$1.03M Sell
20,061
-1,406
-7% -$72.5K 0.04% 317
2024
Q2 		$962K Sell
21,467
-12,816
-37% -$592K 0.04% 308
2024
Q1 		$1.6M Sell
34,283
-5,851
-15% -$229K 0.06% 207
2023
Q4 		$1.43M Buy
40,134
+6,308
+19% +$193K 0.06% 254
2023
Q3 		$1.01M Buy
33,826
+8,230
+32% +$170K 0.06% 280
2023
Q2 		$461K Buy
25,596
+1,193
+5% +$23.8K 0.02% 540
2023
Q1 		$392K Buy
+24,403
New +$452K 0.02% 597

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Profund Advisors's CRNX Position: Q2 2026 in Review

Profund Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 19% in Q2 2026, buying an estimated $55.5K and bringing the position to 9,508 shares worth $356K. The position accounts for 0.01% of the portfolio, ranked #704.

Profund Advisors first reported a position in CRNX in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.6M in Q1 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Profund Advisors held 9,508 shares of Crinetics Pharmaceuticals worth $356K as of Q2 2026.
  • Profund Advisors bought 1,493 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $55.5K.
  • Crinetics Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #704 holding.
  • Profund Advisors first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Crinetics Pharmaceuticals position peaked at $1.6M in Q1 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.